Published in Infect Immun on January 01, 1983
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin Diagn Lab Immunol (1998) 1.93
Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun (2001) 1.59
Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3. J Exp Med (1985) 1.57
Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun (2003) 1.54
Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev (1993) 1.45
Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect Immun (1983) 1.31
Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae. Clin Microbiol Rev (1989) 1.29
Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun (1990) 1.26
Antifungal activity of a human antiglucuronoxylomannan antibody. Clin Diagn Lab Immunol (1998) 1.16
Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect Immun (1999) 1.13
Role of complement in host defense against pneumococcal otitis media. Infect Immun (2009) 1.09
Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci. Infect Immun (2002) 1.09
Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae. Infect Immun (1985) 1.08
The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi. Infect Immun (2010) 1.06
Inhibition of C3 deposition on Streptococcus equi subsp. equi by M protein: a mechanism for survival in equine blood. Infect Immun (1994) 1.00
Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. Infect Immun (2012) 0.98
Capsular polysaccharide regulates neutrophil complement receptor interactions with type III group B streptococci. Infect Immun (1993) 0.98
Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect Immun (2000) 0.97
A point mutation in cpsE renders Streptococcus pneumoniae nonencapsulated and enhances its growth, adherence and competence. BMC Microbiol (2014) 0.97
Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia. Infect Immun (2001) 0.96
Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages. Infect Immun (2008) 0.93
Direct evidence that decreased serum opsonization of Streptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency. J Clin Invest (1987) 0.92
Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats. Infect Immun (2006) 0.92
Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans. Infect Immun (2006) 0.88
Biochemical activities of Streptococcus pneumoniae serotype 2 capsular glycosyltransferases and significance of suppressor mutations affecting the initiating glycosyltransferase Cps2E. J Bacteriol (2013) 0.87
Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo. Clin Vaccine Immunol (2010) 0.87
Evaluation of C3b/C3bi opsonization and chemiluminescence with selected yeasts and bacteria using sera of different opsonic potential. Immunology (1986) 0.82
Contribution of different pneumococcal virulence factors to experimental meningitis in mice. BMC Infect Dis (2013) 0.82
Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease. Infect Immun (2005) 0.78
Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans. Infect Immun (2006) 0.77
Could proteomic research deliver the next generation of treatments for pneumococcal meningitis? Interdiscip Perspect Infect Dis (2009) 0.76
Pathogenesis of bacterial meningitis: contributions by experimental models in rabbits. Infection (1984) 0.75
The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys (1969) 6.55
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation. J Immunol (1972) 2.89
Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol (1978) 2.40
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet (1981) 2.29
Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M: implications for the mechanism of resistance to phagocytosis. Infect Immun (1979) 2.07
Activation of the alternative pathway by pneumococcal cell walls. J Immunol (1977) 1.89
The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus. J Immunol (1976) 1.80
Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall. J Immunol (1980) 1.54
The Forssman antigen of pneumococcus. Jpn J Exp Med (1967) 1.54
The avidin-biotin complex in affinity cytochemistry. Methods Enzymol (1979) 1.53
Biotinylation of human C3. Mol Immunol (1982) 1.02
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The hormone resistin links obesity to diabetes. Nature (2001) 15.49
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Molecular basis for cytadsorption of Mycoplasma pneumoniae. J Bacteriol (1982) 5.52
A newly discovered mycoplasma in the human urogenital tract. Lancet (1981) 5.45
Mycoplasma pneumoniae infection: role of a surface protein in the attachment organelle. Science (1982) 5.08
Symposium on the fine structure and replication of bacteria and their parts. 3. Bacterial cell-wall replication followed by immunofluorescence. Bacteriol Rev (1965) 4.75
Minicells of Bacillus subtilis. J Bacteriol (1973) 4.70
Cortical language localization in left, dominant hemisphere. An electrical stimulation mapping investigation in 117 patients. J Neurosurg (1989) 4.18
Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A (1995) 3.87
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Attainment and adjustment in two geographical areas. I--The prevalence of psychiatric disorder. Br J Psychiatry (1975) 3.79
Ultrastructure of a temperature-sensitive rod- mutant of Bacillus subtilis. J Bacteriol (1970) 3.70
Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation (1990) 3.52
Hypoglycemic symptoms and frequency of severe hypoglycemia in patients treated with human and animal insulin preparations. Diabetes Care (1991) 3.51
Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol (1985) 3.50
Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med (1995) 3.47
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med (1994) 3.24
Autolytic activity associated with competent group H streptococci. J Bacteriol (1971) 3.15
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med (1999) 3.02
A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A (2001) 2.93
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem (2000) 2.71
The parasitophorous vacuole membrane surrounding intracellular Toxoplasma gondii functions as a molecular sieve. Proc Natl Acad Sci U S A (1994) 2.70
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Morphology, ultrastructure, and bacteriophage infection of the helical mycoplasma-like organism (Spiroplasma citri gen. nov., sp. nov.) cultured from "stubborn" disease of citrus. J Bacteriol (1973) 2.57
Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science (1996) 2.55
Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care (1987) 2.50
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance. J Clin Invest (1988) 2.38
Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem (1996) 2.37
Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med (1999) 2.36
Growth, sporulation, and enzyme defects of glucosamine mutants of Bacillus subtilis. J Bacteriol (1970) 2.34
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet (1981) 2.29
The Toxoplasma gondii rhoptry protein ROP 2 is inserted into the parasitophorous vacuole membrane, surrounding the intracellular parasite, and is exposed to the host cell cytoplasm. J Cell Biol (1994) 2.26
Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 in cultured lymphocytes. J Clin Invest (1996) 2.25
The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid. Proc Natl Acad Sci U S A (1994) 2.22
Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia (1983) 2.18
Attributes of potential utility in differentiating among "group H" streptococci or Streptococcus sanguis. J Dent Res (1976) 2.17
Association of host cell endoplasmic reticulum and mitochondria with the Toxoplasma gondii parasitophorous vacuole membrane: a high affinity interaction. J Cell Sci (1997) 2.16
CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem (2000) 2.15
Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J Cell Biol (1993) 2.10
Safe haven: the cell biology of nonfusogenic pathogen vacuoles. Annu Rev Microbiol (1997) 2.07
Integrin alpha v beta 3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor alpha 5 beta 1. J Cell Biol (1994) 2.05
Transformation of streptococci in chemically defined media. Biochem Biophys Res Commun (1967) 2.04
Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol (1999) 2.03
Sleep and depression--results from psychobiological studies: an overview. Biol Psychol (2001) 2.02
Effect of age on excess mortality in obesity. JAMA (1999) 2.01
Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J Cell Biol (2000) 1.96
Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia (1997) 1.95
A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis. J Cell Biol (1989) 1.95
Lipopolysaccharide size and distribution determine serum resistance in Salmonella montevideo. J Bacteriol (1987) 1.93
Oxidative damage to DNA: formation, measurement, and biological significance. Rev Physiol Biochem Pharmacol (1997) 1.91
Glucose metabolism in perfused skeletal muscle. Effects of starvation, diabetes, fatty acids, acetoacetate, insulin and exercise on glucose uptake and disposition. Biochem J (1976) 1.90
The formation of glutamine and alanine in skeletal muscle. J Biol Chem (1974) 1.90
CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J Cell Biol (1994) 1.89
Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest-Düsseldorf Study. Diabetologia (1987) 1.87
Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol (1984) 1.87
The critical role of complement in experimental pneumococcal sepsis. J Infect Dis (1980) 1.87
Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia (1990) 1.84
Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J Virol (1998) 1.83
C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by Salmonella montevideo. J Immunol (1986) 1.82
Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol (1995) 1.82
Degradation of group A streptococcal cell walls by egg-white lysozyme and human lysosomal enzymes. Infect Immun (1972) 1.80
Isolation of bacteriophages from group H streptococci. J Virol (1972) 1.79
An immobile subset of plasma membrane CD11b/CD18 (Mac-1) is involved in phagocytosis of targets recognized by multiple receptors. J Immunol (1989) 1.79
NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med (1983) 1.79
Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J (1974) 1.78
Lysis and lysogenization of groups A, C, and G streptococci by a transducing bacteriophage induced from a group G Streptococcus. J Virol (1971) 1.76
Kinetics and pattern of organelle exocytosis during Toxoplasma gondii/host-cell interaction. Parasitol Res (1993) 1.76
Urogenital mycoplasma infections of man: a review with observations on a recently discovered mycoplasma. Isr J Med Sci (1981) 1.76
The parasitophorous vacuole membrane surrounding Plasmodium and Toxoplasma: an unusual compartment in infected cells. J Cell Sci (1998) 1.73
CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J Immunol (1989) 1.72
Glucose metabolism in perfused skeletal muscle. Interaction of insulin and exercise on glucose uptake. Biochem J (1975) 1.71
The Toxoplasma gondii protein ROP2 mediates host organelle association with the parasitophorous vacuole membrane. J Cell Biol (2001) 1.69
THE ORGANIZATION OF SCIENTIFIC MEN. Science (1924) 1.69
Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol (1997) 1.68
Transendothelial migration of neutrophils involves integrin-associated protein (CD47). Proc Natl Acad Sci U S A (1995) 1.68
Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care (1985) 1.67
Effective and safe translation of intensified insulin therapy to general internal medicine departments. Diabetologia (1993) 1.67
Issues in the measurement of satisfaction with treatment. Am J Manag Care (1997) 1.67
Lysis and protoplast formation of group B streptococci by mutanolysin. Infect Immun (1980) 1.67
Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest (1990) 1.66
Ligand specificity of purified complement receptor type three (CD11b/CD18, alpha m beta 2, Mac-1). Indirect effects of an Arg-Gly-Asp (RGD) sequence. J Immunol (1993) 1.65
Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med (1981) 1.65
Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains. J Cell Biol (1998) 1.63
Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis (1995) 1.63
Purification of a mycobacterial adhesin for fibronectin. Infect Immun (1993) 1.63